List of Excipients in Branded Drug GAVILYTE - C

« Back to Dashboard

Generic Drugs Containing GAVILYTE - C

Company	Ingredient	NDC	Excipient
Lupin PharmaceuticalsInc	polyethylene glycol-3350 and electrolytes with flavor pack	43386-060	MALTODEXTRIN
Lupin PharmaceuticalsInc	polyethylene glycol-3350 and electrolytes with flavor pack	43386-060	SACCHARIN SODIUM

What are the Most Frequently-Used Excipients in GAVILYTE - C?

# Of NDCs	Excipient
1	MALTODEXTRIN
1	SACCHARIN SODIUM

GaviLyte-C Excipient Strategy and Commercial Opportunities

Last updated: October 3, 2026

GaviLyte-C is a polyethylene glycol 3350 electrolyte bowel-preparation powder for oral solution. Its commercial position depends less on active-ingredient differentiation than on excipient control, taste, reconstitution, packaging, supply reliability, and the ability to support lower-volume or improved-adherence products. The formulation uses established, low-cost excipients and has limited traditional patent protection. The main competitive opportunity is therefore product optimization within FDA pharmaceutical-equivalence and labeling constraints.

What is GaviLyte-C and how is it formulated?

GaviLyte-C contains polyethylene glycol 3350, sodium sulfate, sodium bicarbonate, sodium chloride, and potassium chloride. The powder is reconstituted with water to produce approximately 4 liters of oral solution.[1]

Component	Approximate quantity per 4 L	Functional role
Polyethylene glycol 3350	236 g	Osmotic laxative; retains water in the gastrointestinal tract
Sodium sulfate	22.74 g	Electrolyte replacement and osmotic activity
Sodium bicarbonate	6.74 g	Buffer and electrolyte
Sodium chloride	5.86 g	Electrolyte replacement
Potassium chloride	2.97 g	Potassium replacement
Flavoring	Label-specific	Taste masking
Sodium saccharin	Label-specific	Sweetening

The electrolyte combination is designed to reduce clinically significant net electrolyte absorption or loss during bowel cleansing. The product is indicated for colon cleansing before colonoscopy and other examinations.[1]

GaviLyte-C is a powder for solution rather than a ready-to-drink liquid. That format reduces shipping weight and improves storage efficiency, but it transfers preparation work to the patient or caregiver.

What excipients are protected by the GaviLyte-C formulation?

The key excipient strategy is functional rather than proprietary. Polyethylene glycol 3350 and the inorganic electrolytes are established pharmaceutical materials with broad commercial availability. The principal formulation-sensitive variables are particle properties, blend uniformity, moisture control, flavor composition, and reconstitution performance.

Polyethylene glycol 3350

Polyethylene glycol 3350 is the primary osmotic agent. Its molecular-weight distribution, residual moisture, bulk density, particle size, and flow characteristics can affect:

• Powder segregation during filling
• Dissolution time
• Container fill accuracy
• Clumping during storage
• Mouthfeel after reconstitution
• Manufacturing yield

A supplier change may require comparability work even when the material meets the same compendial specification. A company seeking a lower-cost source should evaluate molecular-weight distribution, impurities, water content, microbiological quality, and lot-to-lot dissolution behavior.

Sodium sulfate, sodium bicarbonate, sodium chloride, and potassium chloride

The electrolyte salts are inexpensive but operationally important. Sodium bicarbonate is moisture-sensitive and can contribute to caking or loss of powder flow if packaging does not provide adequate moisture protection. Potassium chloride and sodium chloride also influence taste intensity and ionic strength.

The salt blend must remain homogeneous through blending, transfer, filling, and shipment. Differences in particle size or density can produce segregation, which creates a dose-uniformity risk in multi-ingredient powder products.

Flavoring and sweetening system

Taste is the most commercially relevant excipient opportunity. The electrolyte load produces a salty, mineral-like taste that can drive incomplete intake, vomiting, or delayed administration. Lemon flavor and sodium saccharin are used to make the reconstituted solution more acceptable, but the finished product remains a high-volume electrolyte solution.

Potential flavor-system workstreams include:

• Citrus flavor systems with lower bitterness perception
• Alternative sweeteners compatible with the electrolyte matrix
• Reduced sulfur or mineral aftertaste
• Flavor stability over the labeled shelf life
• Improved palatability after refrigeration
• Flavor systems that remain acceptable when diluted or consumed in split doses

Any flavor modification must be assessed for pharmaceutical equivalence, stability, impurity formation, microbial risk, and labeling impact. A flavor change is not automatically a commercially unrestricted change for an ANDA product.

What commercial opportunities exist for GaviLyte-C excipients?

The strongest opportunities are differentiated presentations and adherence improvements, not replacement of the core osmotic system.

Opportunity	Commercial rationale	Main regulatory or technical constraint
Improved flavor system	May reduce incomplete dosing and improve patient acceptance	Must preserve formulation performance and support ANDA or NDA requirements
Smaller powder package	Lowers storage and shipping burden	Must retain the same delivered dose and reconstitution instructions
Single-use reconstitution container	Reduces preparation errors	Packaging cost and container compatibility
Premeasured water or integrated fill line	Improves patient convenience	Higher logistics cost and packaging validation
Split-dose instructions	Aligns with current colonoscopy practice and may improve cleansing	Labeling and clinical-support requirements
Ready-to-drink presentation	Removes reconstitution burden	Higher freight, stability, microbial, and packaging costs
Private-label supply	Expands pharmacy and health-system access	Requires reliable API and excipient supply
Institutional bulk packaging	May reduce unit cost for high-volume centers	Administration and storage controls
Temperature-stable flavor system	Supports pharmacy and home use	Stability data required
Digital adherence packaging	Helps patients complete a 4-liter regimen	Commercial rather than formulation-based differentiation

The most defensible near-term strategy is a high-quality powder product with improved taste, robust moisture protection, and packaging that reduces preparation errors. A smaller-volume product would require a different formulation concept or a higher concentration, both of which could affect tolerability, osmotic behavior, electrolyte exposure, and clinical performance.

How does GaviLyte-C compare with competing bowel preparations?

GaviLyte-C competes against large-volume PEG-electrolyte products, lower-volume sulfate-based products, and tablet-based regimens.

Product category	Typical volume burden	Excipient strategy	Main commercial advantage
GaviLyte-C and similar PEG-electrolyte solutions	Approximately 4 L	PEG 3350 plus balanced electrolytes, flavor, sweetener	Established cleansing profile and broad generic availability
Lower-volume PEG products	Approximately 2 L plus additional clear liquids	Higher concentration or supplemental liquid strategy	Lower primary product volume
Sulfate-based solutions	Lower than traditional 4-L PEG products	Sulfate salts, flavoring, acidulants or buffers, sweeteners	Patient convenience
Tablet-based preparations	Water required with tablets	Solid dosage form with purgative salts	Avoids drinking a large flavored solution
Magnesium-containing preparations	Product-dependent	Magnesium salts and other osmotic agents	Low volume in selected patients

The tradeoff is between volume, electrolyte composition, taste, renal and cardiac considerations, cost, and physician familiarity. GaviLyte-C has a cost-oriented position, but high volume creates a clear adherence disadvantage against lower-volume products.

What FDA regulatory status and Orange Book status apply to GaviLyte-C?

GaviLyte-C is an FDA-approved prescription bowel preparation marketed as a generic-equivalent PEG-electrolyte product. FDA labeling identifies polyethylene glycol 3350, sodium sulfate, sodium bicarbonate, sodium chloride, and potassium chloride as the active ingredients in the formulation.[1]

The FDA Orange Book is the controlling source for current approval, therapeutic-equivalence, patent, and exclusivity information.[2] Product-specific commercial analysis should distinguish the following:

Regulatory issue	GaviLyte-C assessment
FDA pathway	Abbreviated New Drug Application or generic-equivalent pathway
Dosage form	Powder for oral solution
Reference-product relationship	PEG-electrolyte bowel-preparation category
Current regulatory barrier	No apparent market-wide exclusivity barrier in the public product framework
Biosimilar pathway	Not applicable; GaviLyte-C is a small-molecule formulation
Orange Book review	Required for current applicant, therapeutic-equivalence, patent, and exclusivity status
Label control	Material changes may require FDA approval

The product’s regulatory value is tied to pharmaceutical equivalence, manufacturing consistency, stability, and labeling compliance. Excipients that are common in the food or supplement markets still must meet pharmaceutical quality requirements when used in an approved drug product.

What patents protect GaviLyte-C and its excipient formulation?

The commercial formulation is unlikely to be protected by a meaningful, durable patent estate directed solely to the basic combination of PEG 3350 and electrolyte salts. The ingredients and general bowel-preparation concept are longstanding. The main potential sources of intellectual-property protection are:

1. A specific flavor or taste-masking composition.
2. A novel low-volume concentration.
3. A specialized packaging or reconstitution system.
4. A manufacturing process that improves blend uniformity or shelf life.
5. A dosing regimen or method of use.
6. A combination with a particular diagnostic procedure or patient population.

These rights may be relevant to a new product, but they do not automatically block marketing of a conventional GaviLyte-C-equivalent powder.

Patent expiration and Paragraph IV risk

A conventional GaviLyte-C-equivalent product would generally face limited Paragraph IV risk if no active Orange Book-listed patents cover the reference product. Paragraph IV certifications matter only when an ANDA applicant is addressing patents listed against the relevant reference product. The applicant must review the current Orange Book entry and any applicable patent-listing history before relying on that conclusion.[2]

For a new lower-volume, reformulated, or taste-masked product, patent risk would shift from the legacy PEG-electrolyte composition to competitor patents covering:

• Concentrated electrolyte solutions
• Specific sulfate or PEG ratios
• Flavor systems
• Low-volume bowel-preparation regimens
• Packaging and dosing systems
• Methods that use split dosing or reduced intake volume

What patent litigation or settlement agreements affect GaviLyte-C?

No material public litigation or settlement agreement is inherent in the basic GaviLyte-C excipient formulation. A litigation review should separate three categories:

Product-specific litigation

This includes patent, trademark, manufacturing, or labeling disputes involving a GaviLyte-C manufacturer or distributor. The relevant defendants may include the ANDA sponsor, contract manufacturer, or private-label distributor.

Reference-product litigation

This concerns the branded reference product or other PEG-electrolyte products. It may affect the timing of generic entry for a specific product but does not necessarily restrict GaviLyte-C.

Competitive formulation litigation

This is more relevant to new commercial opportunities. A company developing a lower-volume or taste-improved product could face claims involving formulation ratios, methods of use, packaging, or flavor systems.

There is no biosimilar litigation issue because GaviLyte-C is not a biologic. FDA exclusivity analysis should focus on small-molecule generic and 505(b)(2) pathways rather than biosimilar interchangeability.

How strong is the GaviLyte-C patent estate?

The basic patent estate is weak from a product differentiation perspective because the formulation relies on old, widely used excipients. Commercial defensibility depends on execution.

Asset	Patent strength	Commercial relevance
PEG 3350 and electrolyte combination	Low for new broad claims	Supports low-cost generic competition
Specific flavor system	Moderate if technically distinctive	May support patient-preference differentiation
Moisture-resistant packaging	Moderate	Can protect shelf-life and handling advantages
Lower-volume formulation	Potentially stronger	Requires clinical and regulatory development
Manufacturing process	Moderate if non-obvious and measurable	Can improve margins and supply reliability
Brand and distribution	Non-patent protection	Important in pharmacy and institutional channels
Clinical adherence evidence	No direct patent protection	Can support formulary and prescriber adoption

A new entrant should not rely on the basic active-ingredient combination for market exclusivity. It should build a layered strategy around formulation, packaging, trademarks, manufacturing know-how, and clinical usability data.

What manufacturing and supply-chain barriers affect GaviLyte-C?

The ingredient cost is likely low relative to finished-product manufacturing and distribution. The critical barriers are quality-system and supply-chain controls.

Manufacturing risks

• Segregation of salts and PEG during blending
• Moisture uptake by sodium bicarbonate and the finished blend
• Inaccurate fill weight
• Incomplete dissolution
• Flavor loss or degradation
• Container-closure leakage
• Powder caking
• Inconsistent bulk density
• Cross-contamination in shared facilities

Packaging requirements

A moisture-barrier pouch or bottle is central to product quality. Packaging development should evaluate:

• Water-vapor transmission rate
• Seal integrity
• Container compatibility
• Powder flow after storage
• Label readability
• Reconstitution markings
• Child-resistant or tamper-evident features where applicable
• Shipping exposure to heat and humidity

USP general chapters and FDA drug-quality expectations apply to incoming materials, manufacturing controls, packaging systems, and finished-product testing.[3][4]

Which companies are challenging or competing with GaviLyte-C?

Competition comes from generic manufacturers, branded bowel-preparation companies, private-label suppliers, and manufacturers of low-volume or tablet-based regimens. The relevant competitive groups include:

• Suppliers of PEG 3350-electrolyte powders
• Manufacturers of lower-volume sulfate solutions
• Branded colonoscopy-preparation companies
• Contract manufacturers offering private-label bowel preparations
• Tablet-based bowel-preparation developers
• Pharmacy and health-system purchasing groups

The main competitive variables are acquisition cost, therapeutic-equivalence status, supply continuity, taste, volume burden, and payer or formulary acceptance. Manufacturer-level market share and product revenue are not reliably disclosed for GaviLyte-C as a standalone product. Revenue exposure should therefore be modeled using prescription volume, average net price, channel mix, and substitution rates rather than relying on public company reporting.

What generic launch scenarios exist for GaviLyte-C?

Base case: conventional generic powder

A new entrant markets a pharmaceutically equivalent 4-liter PEG-electrolyte powder. Competition is primarily price-based. Success depends on FDA approval, reliable manufacturing, wholesaler access, and avoiding backorders.

Upside case: taste-improved powder

The entrant retains the established electrolyte architecture but improves flavor and packaging. The product may obtain better prescriber and patient acceptance, but the commercial premium must offset development, validation, and promotional costs.

Differentiated case: lower-volume product

A lower-volume formulation competes directly on adherence and convenience. It has greater development risk, potentially stronger intellectual-property opportunities, and a more demanding clinical and regulatory pathway.

Institutional case: private-label supply

A manufacturer supplies pharmacies, hospitals, ambulatory surgery centers, or physician networks under private labels. This model can increase volume but usually compresses net price and shifts value toward supply reliability.

What excipient strategy should a GaviLyte-C competitor use?

The recommended strategy is to preserve the established PEG-electrolyte performance while improving the patient-use experience.

1. Use qualified pharmaceutical-grade PEG 3350 with tight control of molecular-weight distribution and moisture.
2. Engineer salt particle-size compatibility to limit segregation.
3. Select a moisture-barrier container supported by accelerated and long-term stability data.
4. Screen citrus and non-citrus flavor systems against the full electrolyte matrix.
5. Evaluate sweetener combinations for aftertaste, stability, and regulatory acceptability.
6. Design the package around clear reconstitution instructions and split-dose use.
7. Protect differentiated features through formulation, packaging, process, and trademark rights.
8. Avoid assuming that a food-grade flavor or commodity excipient creates regulatory or patent differentiation.
9. Build dual sourcing for PEG 3350 and key electrolyte salts.
10. Use patient-preference and completion-rate evidence to support formulary positioning.

Key Takeaways

• GaviLyte-C is a 4-liter PEG 3350-electrolyte bowel-preparation powder.
• Its core excipients are established and generally low-cost, so broad composition patents offer limited protection.
• Flavor, sweetening, moisture protection, reconstitution convenience, and packaging are the strongest formulation opportunities.
• A conventional generic launch is primarily a price, supply, and FDA-equivalence business.
• A lower-volume or ready-to-drink product offers greater differentiation but requires more extensive development.
• Biosimilar risk does not apply because GaviLyte-C is a small-molecule formulation.
• Paragraph IV exposure depends on the current Orange Book listing for the relevant reference product and any listed patents.
• Public standalone revenue data for GaviLyte-C are limited; commercial modeling should use prescription, price, channel, and substitution assumptions.
• Manufacturing know-how and supply reliability may be more valuable than the underlying excipient composition.

FAQs

Is GaviLyte-C the same as GoLYTELY?

GaviLyte-C is a PEG 3350-electrolyte bowel preparation with a formulation architecture comparable to traditional 4-liter PEG-electrolyte products. Exact labeling, manufacturer, flavor, packaging, and regulatory status must be checked product by product.

Can a company change the flavor of GaviLyte-C without a new approval?

A flavor change may require regulatory review because flavoring affects the approved formulation, stability, specifications, and labeling. The required pathway depends on the scale and nature of the change.

Are PEG 3350 and electrolyte salts patentable in a new bowel preparation?

The individual ingredients and basic combination generally provide weak broad patent positions because they are established materials. A patent strategy is more credible for a novel concentration, taste-masking system, packaging configuration, manufacturing process, or method of use.

Does GaviLyte-C face biosimilar competition?

No. Biosimilar regulation applies to biological products. GaviLyte-C is a small-molecule drug product and competes with generic, branded, lower-volume, and tablet-based bowel preparations.

What is the largest commercial weakness of GaviLyte-C?

The primary weakness is the approximately 4-liter intake burden. A competitor that improves palatability, reduces preparation friction, or provides a lower-volume regimen could gain market share even if its ingredient cost is higher.

References

1. DailyMed. (n.d.). GaviLyte-C: Polyethylene glycol 3350, sodium chloride, sodium bicarbonate, and potassium chloride powder for solution. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

3. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.

4. U.S. Food and Drug Administration. (2011). Q8(R2) pharmaceutical development. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q8r2-pharmaceutical-development